Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,084 recruiting studies in this area right now.
By phase
- Not applicable2,111
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California407
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,084 total
- NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Basking Ridge, New JerseyAges 18 years+ - NCT07249905RecruitingPhase 1/Phase 2
Testing MDX2003 for people with relapsed B-cell lymphoma
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
Richmond, VictoriaAges 18 years+ - NCT07250217Recruiting
Study of AML epigenetic markers in older adults
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
Mulhouse, AlsaceAges 60 years+ - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Birmingham, AlabamaAges 18–39 - NCT06234904RecruitingPhase 1
IBR733 cell therapy for acute myeloid leukemia
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Suzhou, JiangsuAges 18–74 - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07585760RecruitingPhase 2
Study of CM336 and Isatuximab for new multiple myeloma with kidney problems
This trial tests a combination of two drugs, CM336 and Isatuximab, for people newly diagnosed with multiple myeloma that has caused kidney damage. The goal is to see if this treatment can help control the myeloma while also addressing the kidney issues.
TianjinAges 18–80 - NCT07680868Recruiting
Caris Chromoseq data collection for blood cancers
This study collects data from a special genetic test called Caris Chromoseq for people with certain blood cancers. It aims to learn more about these diseases and possibly guide better treatments.
Phoenix, ArizonaAges 18 years+ - NCT05022459Recruiting
Prevent bleeding in kids with Hemophilia A who play sports
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Little Rock, ArkansasAges 6–19 - NCT03990428Recruiting
Support program study for caregivers of rare blood cancers
This study looks at what support caregivers of people with Erdheim-Chester disease and related rare conditions need. It may help improve caregiver support so families cope better while the patient is being treated.
New York, New YorkAges 18 years+ - NCT05699005RecruitingPhase 1
Personalized or standard blood transfusion during heart-lung machine
This trial tests whether giving blood in a personalized way, instead of a standard approach, is better for people on a heart-lung bypass machine (VA-ECMO) for heart-related shock. It may help find a safer blood transfusion strategy while you are critically ill.
Lille, NORDAges 18 years+ - NCT03593759RecruitingPhase 3
Testing treatment for active cardiac sarcoidosis heart rhythm and function
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
New Haven, ConnecticutAges 18 years+ - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Boston, MassachusettsAges 18–130 - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT04819841RecruitingPhase 1/Phase 2
Gene correction using your own stem cells to improve sickle disease
This trial tests a gene-correction treatment that changes sickle hemoglobin (HbS) into normal hemoglobin (HbA) using your own stem cells. It may help reduce severe sickle cell complications for people with severe disease who meet specific safety and medical criteria.
Los Angeles, CaliforniaAges 12–50 - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT00001620Enrolling by invitation
NIH screening to see which blood studies fit you
This study is a general screening step at the NIH Clinical Center to check whether you might qualify for other NHLBI research protocols. It helps match you (or a donor/healthy volunteer) to the right study and confirms you can consent to participate.
Bethesda, MarylandAges 2–100 - NCT07649031Recruiting
MRI Scanning to Monitor Mouth Cancer Risk in Fanconi Anemia
This study uses MRI (a safe imaging scan) to detect and track dangerous changes in the mouth of people with Fanconi Anemia, a rare genetic condition. The goal is to find a better way to catch oral cancer early.
Minneapolis, MinnesotaAges 18 years+ - NCT02560883Recruiting
Hairy cell leukemia patient data registry
This registry collects information about people with classic and variant hairy cell leukemia. It helps doctors learn from real-world patient data and may improve future care.
Miami, FloridaAges 18 years+ - NCT07304011RecruitingPhase 2
Olutasidenib and azacitidine for IDH1-mutated AML after venetoclax
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Sacramento, CaliforniaAges 18 years+ - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07254312Recruiting
Venetoclax blood levels and side effects in AML
This trial checks how the amount of venetoclax in your blood relates to side effects after you are in remission from AML. It aims to help doctors find the safest dose for you.
Pavia, PaviaAges Any age
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,084 recruiting hematology studies from the U.S. registry right now, out of 7,742 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.